» Articles » PMID: 37891819

An In Vitro Brain Tumour Model in Organotypic Slice Cultures Displaying Epileptiform Activity

Overview
Journal Brain Sci
Publisher MDPI
Date 2023 Oct 28
PMID 37891819
Authors
Affiliations
Soon will be listed here.
Abstract

Brain tumours have significant impacts on patients' quality of life, and current treatments have limited effectiveness. To improve understanding of tumour development and explore new therapies, researchers rely on experimental models. However, reproducing tumour-associated epilepsy (TAE) in these models has been challenging. Existing models vary from cell lines to in vivo studies, but in vivo models are resource-intensive and often fail to mimic crucial features like seizures. In this study, we developed a technique in which normal rat organotypic brain tissue is implanted with an aggressive brain tumour. This method produces a focal invasive lesion that preserves neural responsiveness and exhibits epileptiform hyperexcitability. It allows for real-time imaging of tumour growth and invasion for up to four weeks and microvolume fluid sampling analysis of different regions, including the tumour, brain parenchyma, and peritumoral areas. The tumour cells expand and infiltrate the organotypic slice, resembling in vivo behaviour. Spontaneous seizure-like events occur in the tumour slice preparation and can be induced with stimulation or high extracellular potassium. Furthermore, we assess extracellular fluid composition in various regions of interest. This technique enables live cell confocal microscopy to record real-time tumour invasion properties, whilst maintaining neural excitability, generating field potentials, and epileptiform discharges, and provides a versatile preparation for the study of major clinical problems of tumour-associated epilepsy.

Citing Articles

Hybrid-integrated devices for mimicking malignant brain tumors ("tumor-on-a-chip") for development of targeted drug delivery and personalized therapy approaches.

Zimina T, Sitkov N, Gareev K, Mikhailova N, Combs S, Shevtsov M Front Med (Lausanne). 2024; 11:1452298.

PMID: 39629230 PMC: 11611596. DOI: 10.3389/fmed.2024.1452298.

References
1.
Gomes S, Miguel J, Azema L, Eimer S, Ries C, Dausse E . (99m)Tc-MAG3-aptamer for imaging human tumors associated with high level of matrix metalloprotease-9. Bioconjug Chem. 2012; 23(11):2192-200. DOI: 10.1021/bc300146c. View

2.
Sampson J, Ashley D, Archer G, Fuchs H, Dranoff G, Hale L . Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery. 1997; 41(6):1365-72; discussion 1372-3. DOI: 10.1097/00006123-199712000-00024. View

3.
Buckingham S, Campbell S, Haas B, Montana V, Robel S, Ogunrinu T . Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011; 17(10):1269-74. PMC: 3192231. DOI: 10.1038/nm.2453. View

4.
Pasqualini C, Kozaki T, Bruschi M, Nguyen T, Minard-Colin V, Castel D . Modeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors. Neuron. 2020; 108(6):1025-1044. DOI: 10.1016/j.neuron.2020.09.018. View

5.
Shin J, Kizilbash S, Robinson S, Uhm J, Hammack J, Lachance D . Seizures in patients with primary brain tumors: what is their psychosocial impact?. J Neurooncol. 2016; 128(2):285-91. DOI: 10.1007/s11060-016-2108-y. View